Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Eosinophilic cholangitis (EC) is a rare benign disorder of the biliary tract which can cause biliary obstruction. Similar to other disease processes involving the bile ducts, this disorder can pose a difficult diagnostic challenge as it can mimic cholangiocarcinoma.
Methods: A systematic search of the scientific literature was carried out using PubMed to access all publications related to EC. Search keywords that were utilized included "eosinophilic cholangitis," "etiology," "treatment," and "obstructive jaundice." Results. Twenty-three cases of EC have been reported. Nineteen patients (82.6%) who presented with EC remain disease-free; 15 of these 19 patients (78.9%) with followup time remain disease-free at a mean of 9.7 months (range, 2-24 months).
Conclusion: EC is a rare form of biliary obstruction which can masquerade as a malignancy. Unlike cholangiocarcinoma, EC occurs more commonly in younger patients and in men. Most patients will require surgical treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976516 | PMC |
| http://dx.doi.org/10.1155/2010/906496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024.
Mayo Clin Proc
September 2025
Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill, NC.
This review addresses selected topics in gastroenterology and hepatology that are of interest and relevance to general internists. The topics were selected on the basis of publications in 2024 in top general medicine journals (New England Journal of Medicine, Journal of the American Medical Association, Annals of Internal Medicine, Lancet), often complemented with publications in the top gastroenterology journals pertaining to the same themes. General internists may be the primary providers for some of these diseases or the first to evaluate symptoms-such as uncontrolled heartburn; dysphagia, which is increasingly recognized as being associated with allergic mechanisms including eosinophil infiltration of the esophagus; irritable bowel syndrome; and the effects of incretin therapies (glucagon-like peptide 1 and glucagon-dependent insulinotropic peptide agonists) on obesity, metabolic-associated steatohepatitis, or steatotic liver diseases-and to screen for colorectal cancer by novel blood or stool markers.
View Article and Find Full Text PDFLiver Transplantation for Isolated Langerhans Cell Histiocytosis in an Adult.
Case Rep Hematol
June 2025
University of Miami Miller School of Medicine, Miami, Florida, USA.
Langerhans cell histiocytosis (LCH) is a rare disease of proliferation of histiocytic disorder composed of histologically bland Langerhans cells mixed with reactive mononuclear and granulocytic cells, and often accompanied by eosinophils. These cells are characterized by expression of CD1a, S-100 and Langerin proteins. The clinical presentation ranges from indolent to aggressive, depending on the anatomic site involved which can be unifocal, multifocal, unisystemic, or multifocal and multisystemic disease.
View Article and Find Full Text PDFEradication Therapy-Associated Drug-Induced Liver Injury in a Patient With Primary Biliary Cholangitis.
Gastro Hep Adv
May 2025
Department of Gastroenterology, Nagano Red Cross Hospital, Nagano City, Nagano, Japan.
Drug-induced liver injury (DILI) is a rare but serious complication of eradication therapy, especially in patients with pre-existing liver disease. We report a 75-year-old man with well-controlled primary biliary cholangitis (PBC) who developed jaundice and pruritus after treatment with vonoprazan, amoxicillin, and clarithromycin. Liver biopsy showed an enlarged portal area, enlarged hepatocytes around the central vein, eosinophil infiltration, and focal necrosis, but PBC deterioration was ruled out.
View Article and Find Full Text PDFHepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.
Eur J Gastroenterol Hepatol
August 2025
Gastroenterology Department, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
Vedolizumab is a humanized antiintegrin α4β7 mAb, selective for the intestine, used in the treatment of moderate to severe inflammatory bowel disease. Safety studies show that vedolizumab has a 31% risk of serious adverse events, but reports of hepatotoxicity are rare. Previous case descriptions show that the lesion is mainly cholestatic or mixed, but hepatocellular lesion can also occur.
View Article and Find Full Text PDFSclerosing eosinophilic extrahepatic cholangitis in a cat.
J Comp Pathol
May 2025
Setor de Patologia Veterinária, Departamento de Patologia Clínica Veterinária, Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9090 - Agronomia, Porto Alegre, RS, 91540-000, Brazil.
A 9-year-old female cat was presented to the veterinary hospital with a history of progressive weight loss, anorexia and jaundice. Clinical findings included poor body condition, hypothermia and jaundice. The ultrasound findings were consistent with cholangiohepatitis associated with pancreatitis and the biochemical tests indicated a marked increase in activities of hepatobiliary enzymes (alkaline phosphatase, alanine aminotransferase, gamma-glutamyl transpeptidase).
View Article and Find Full Text PDF